Compare MTEK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEK | BNR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 216.9M |
| IPO Year | 2022 | 2020 |
| Metric | MTEK | BNR |
|---|---|---|
| Price | $1.55 | $29.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 101.9K | 23.5K |
| Earning Date | 03-30-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,375,716.00 | ★ $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $1.03 | $2.18 |
| 52 Week High | $4.27 | $41.72 |
| Indicator | MTEK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 50.03 |
| Support Level | $1.48 | $28.28 |
| Resistance Level | $1.65 | $34.26 |
| Average True Range (ATR) | 0.18 | 3.24 |
| MACD | -0.02 | -1.11 |
| Stochastic Oscillator | 14.08 | 15.56 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.